Trailing-twelve-month (TTM) revenue is $785.23 Million with a year-over-year growth of (1.83%). Revenue represents the total income generated from the company's primary business operations.
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $196,028,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-04 |
| Q4 FY2025Period ended 2025-12-31 | $194,785,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-02-25 |
| Q1 FY2026Period ended 2026-03-31 | $194,006,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-06 |
| Q2 FY2026Period ended 2026-06-30 | $200,411,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-05 |
| TTM revenue | $785,230,000 |
Current P/S: $1,157,742,751 market capitalization ÷ $785,230,000 TTM revenue = 1.47x.
Market capitalization source: FMP quote. Quote observed 2026-10-06T14:15:19.000Z. Latest revenue period ended 2026-06-30.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
Reported quarterly revenue; no daily interpolation. Q2 FY2026 (2026-06-30): $200.41M.
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T14:16:51.529Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2024-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20202020-12-31 · USD | FY20212021-12-31 · USD | FY20222022-12-31 · USD | FY20232023-12-31 · USD | FY20242024-12-31 · USD |
|---|---|---|---|---|---|
| Other Revenue | $62M | $92M | $20M | $20M | $21M |
| Prescription Transactions Revenue | $488M | $593M | $551M | $551M | $578M |
| Subscription Revenue |
$785.23M
$785.23 Million
(1.83%)
vs. $799.87M a year ago (TTM)
+4.47%
5 Year compound annual growth rate
1 Year
(1.83%)
3 Year
+1.76%
5 Year
+4.47%
10 Year
N/A
15 Year
N/A
20 Year
N/A
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2025 | $796.85M | +$4.53M | +0.57% |
| 2024 | $792.32M | +$42.06M | +5.61% |
| 2023 | $750.26M | ($16.29M) | (2.12%) |
| 2022 | $766.55M | +$21.13M | +2.83% |
| 2021 | $745.42M | +$194.72M | +35.36% |
| 2020 |
TTM Growth
(1.83%)
3-Year CAGR
+1.76%
5-Year CAGR
+4.47%
Revenue growth vs the same fiscal quarter in the prior fiscal year, last 26 comparable quarters.
Current FMP quote-based enterprise value / four-quarter revenue Quote observation: 2026-10-06T14:16:51.529Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
| N/A |
| $60M |
| $96M |
| $94M |
| $87M |
| $550.70M |
| +$162.48M |
| +41.85% |
| 2019 | $388.22M | +$138.70M | +55.59% |
| 2018 | $249.52M | +$92.28M | +58.69% |
| 2017 | $157.24M | +$57.86M | +58.23% |
